ARTICLE | Product Development
Second-generation psychedelics are being tested in more conventional clinical trials, and starting to yield impressive efficacy
By Selina Koch, Executive Editor
February 6, 2024 1:59 AM UTC
Psychedelics have gone mainstream. Criminalization and decades of stigma have given way to high expectations for the therapeutic power of psychedelics in an array of mental health contexts.
But even as a large swath of society has done a U-turn in its opinion of psychedelics, investor sentiment has cooled in recent years, as first-generation psychedelic therapies revealed the manifold difficulties of the business model needed to commercialize them. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651351/bringing-psychedelics-into-the-drug-development-fold